The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318

To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]. METHODS: BrUOG-292 and BrUOG-318 were two concurrently run, prospective, single-arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Breakstone, Rimini, Almhanna, Khaldoun, Raufi, Alexander, Beard, Rachel E., Leonard, Kara-Lynne, Renaud, Jennifer, Kastura, Michaela, Dionson, Sopha, Wood, Roxanne, Sturtevant, Ashlee, Dipetrillo, Thomas, Olszewski, Adam, Safran, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles: Gastrointestinal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311474/
https://www.ncbi.nlm.nih.gov/pubmed/35749747
http://dx.doi.org/10.1097/COC.0000000000000928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311474/
https://www.ncbi.nlm.nih.gov/pubmed/35749747
http://dx.doi.org/10.1097/COC.0000000000000928

Ejemplares similares